FORM 3
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden hours per response... 0.5

(Print or Type Responses)
1. Name and Address of Reporting Person *
  Crabtree Gerald W
2. Date of Event Requiring Statement (Month/Day/Year)
08/10/2021
3. Issuer Name and Ticker or Trading Symbol
PharmaCyte Biotech, Inc. [PMCB]
(Last)
(First)
(Middle)
23046 AVENIDA DE LA CARLOTA, SUITE 600
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
__X__ Director _____ 10% Owner
__X__ Officer (give title below) _____ Other (specify below)
Chief Science Officer
5. If Amendment, Date Original Filed(Month/Day/Year)
(Street)

LAGUNA HILLS, CA 92653
6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
(City)
(State)
(Zip)
Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4)
2. Amount of Securities Beneficially Owned
(Instr. 4)
3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)
4. Nature of Indirect Beneficial Ownership
(Instr. 5)
Common Stock 11,200 (1)
D
 

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. SEC 1473 (7-02)
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 4)
2. Date Exercisable and Expiration Date
(Month/Day/Year)
3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)
4. Conversion or Exercise Price of Derivative Security 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)
6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (right to buy) 03/09/2017 03/09/2022 Common Stock 1,000 (1) $ 156 (2) D  
Stock Option (right to buy) 01/01/2018 01/01/2023 Common Stock 1,000 (1) $ 83.7 (2) D  
Stock Option (right to buy) 03/20/2019 03/20/2024 Common Stock 1,000 (1) $ 74.25 (2) D  
Stock Option (right to buy) 01/02/2020 01/01/2025 Common Stock 1,000 (1) $ 61.2 (2) D  
Stock Option (right to buy) 01/01/2021(3) 12/31/2025 Common Stock 1,000 (1) $ 10.05 (2) D  

Reporting Owners

Reporting Owner Name / Address Relationships
Director 10% Owner Officer Other
Crabtree Gerald W
23046 AVENIDA DE LA CARLOTA
SUITE 600
LAGUNA HILLS, CA 92653
  X     Chief Science Officer  

Signatures

/s/ Gerald W. Crabtree 08/31/2021
**Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1) The number of shares has been adjusted to reflect a one-for-1,500 reverse stock split of the Issuer's common stock effected on July 12, 2021 (the "Reverse Split").
(2) The exercise price has been adjusted to reflect the Reverse Split.
(3) The option vested in twelve equal monthly installments beginning on January 1, 2021.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.